{"brief_title": "African-American Heart Failure Trial", "brief_summary": "A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.", "detailed_description": "The overall objective is confirmation of BiDil\u2019s Safety and Efficacy in African-American (AFA) Patients with Moderate to Severe Symptomatic Heart Failure.", "condition": ["Congestive Heart Failure"], "intervention_type": ["Drug"], "intervention_name": ["BiDil"], "criteria": "- African American male or female 18 years or older. - NYHA Class 3 & 4. - Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Heart Failure"], "id": "NCT00047775"}